Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publicado em
- 13 ago 2025
- Citações
- 45
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial
Rainer Fietkau, Michael Ghadimi, Robert Grützmann, Uwe A Wittel, Lutz Jacobasch, Waldemar Uhl, Roland S Croner, Wolf Otto Bechstein, Ulf Peter Neumann, Dirk Waldschmidt et al.
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Pancreatic Neoplasms
- Chemoradiotherapy
- Induction Chemotherapy
- Aged
- Leucovorin
- Deoxycytidine
- Irinotecan
- Fluorouracil
- Humans
Veja também
Estudos relacionados
- A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
- Chemotherapy and radiotherapy for advanced pancreatic cancer
- Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505
- Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial